Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1700670

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ticks
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, following the publication of the UK Health Security Agency report Health Effects of Climate Change (HECC) in the UK: State of the evidence 2023 in January, what steps they are taking to inform health professionals of the heightened risk to public health of (1) Lyme disease, and (2) emerging tick-borne diseases, including tick-borne encephalitis, from an increase in the UK distribution of tick species as a result of a warming climate; and what advice are they providing to those exposed to this risk through work or leisure.
tabling member printed	The Earl of Caithness
uin	HL3728
answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>The UK Health Security Agency (UKHSA) has an active programme to promote awareness of tick-borne diseases among local authorities, health professionals and the public by 2025 in line with the Third National Adaptation Programme. This includes Lyme disease and tick-borne encephalitis. UKHSA has worked to develop a toolkit for local authorities and key stakeholders to raise awareness of the potential risks created by ticks and tick-borne disease, a copy of which is attached. UKHSA also publishes Lyme disease data on Fingertips, which is an open access public health data platform which allows the public, health professionals, and local authorities to view trends, compare indicators and understand the incidence of Lyme disease in their area.</p><p>Clinicians are also engaged via teaching sessions for General Practitioners, seminars for infection specialists, and briefing notes to notify clinicians of the possibility of tick-borne diseases, with detail of compatible signs and symptoms. Disease messaging is shared through media, social, and stakeholder channels at a national and regional level, such as the #BeTickAware campaign which aims to raise awareness in the population, including those at risk of exposure through work or leisure.</p> answering member printed Lord Markham question first answered 23/04/2024 11:38:44 answering member 4948 label Biography information for Lord Markham attachment 1 file name Be_tick_aware_toolkit.pdf title Be_tick_aware_toolkit
tabling member	3310 label Biography information for The Earl of Caithness

1700671

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Shortages
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.
tabling member printed	Lord Carlile of Berriew
uin	HL3729
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> answering member printed Lord Markham grouped question UIN HL3730 question first answered 22/04/2024 15:15:21 answering member 4948 label Biography information for Lord Markham
tabling member	1138 label Biography information for Lord Carlile of Berriew

1700672

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Olanzapine: Shortages
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the impact of the shortage of the psychotropic medication Olanzapine, and what steps they are taking to ensure that such shortages do not affect the health and safety of patients, and wider public safety.
tabling member printed	Lord Carlile of Berriew
uin	HL3730
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> answering member printed Lord Markham grouped question UIN HL3729 question first answered 22/04/2024 15:15:21 answering member 4948 label Biography information for Lord Markham
tabling member	1138 label Biography information for Lord Carlile of Berriew

1700674

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tofersen: Licensing
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3732
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> answering member printed Lord Markham grouped question UIN HL3733 question first answered 22/04/2024 15:05:49 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700675

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tofersen
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3733
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> answering member printed Lord Markham grouped question UIN HL3732 question first answered 22/04/2024 15:05:49 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700683

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Staff
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what is their assessment of the impact of the NHS long-term workforce plan upon the number of specialists such as Parkinson’s nurses in the NHS.
tabling member printed	Baroness Gale
uin	HL3741
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>In June 2023, we published the Long Term Workforce Plan which sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years.</p><p>The Plan commits to double the number of medical places, taking the total number of places to 15,000 by 2031/32 and including a commensurate increase in specialty training places that meets the demands of the NHS in the future. It also commits to increasing adult nursing places by 92%, taking the number of total places up to nearly 38,000 by 2031/32.</p><p>There are a record number of nurses working in the NHS and we have reached our target of 50,000 additional nurses, meaning we have delivered on our commitment six months early. In January 2024 there are over 363,000 nurses working across the NHS, representing over 62,000 more than in September 2019.</p> answering member printed Lord Markham question first answered 22/04/2024 15:39:17 answering member 4948 label Biography information for Lord Markham
tabling member	2503 label Biography information for Baroness Gale

1700684

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Women
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether it is their policy for the NHS to refer to "people who have ovaries" rather than "women" and whether this phraseology has been market tested with women, including those for whom English is a second language, to ensure that it is fully understood.
tabling member printed	Baroness Hayter of Kentish Town
uin	HL3742
answer	answer is ministerial correction date of answer 26/04/2024 answer text <p>It is not Government policy for the National Health Service to refer to ‘people who have ovaries’ and this phraseology has not been market tested. We have been clear that biological sex matters and it is important to use language that recognises the separate health and biological needs of men and women.</p><p>For all sex-specific conditions, we expect the language used to put biological sex, for example “women”, front and centre, with biologically-relevant information relating to specific organs or hormones secondary.</p> answering member printed Lord Markham question first answered 26/04/2024 11:09:53 answering member 4948 label Biography information for Lord Markham
tabling member	4159 label Biography information for Baroness Hayter of Kentish Town